Searchable abstracts of presentations at key conferences in endocrinology

ea0090p688 | Pituitary and Neuroendocrinology | ECE2023

Incidental pituitary macroadenoma: natural history and surgical results

Matei Constantinescu Stefan , Alexopoulou Orsalia , Duprez Thierry , Furnica Raluca , Fomekong Edward , Raftopoulos Christian , Maiter Dominique

Introduction: The Incidental diagnosis of non-functioning pituitary macroadenomas (NPFMA) is becoming more prevalent with the spread of modern imaging techniques. More clinical data about their natural history and surgical results are needed. Methods: We retrospectively analyzed medical files of patients referred to our clinic for an incidental NFPMA between 2010 and 2019. In particular, we compared patients that experienced tumor growth or not during su...

ea0037ep145 | Reproduction, endocrine disruptors and signalling | ECE2015

Analysing by decade, testosterone undecanoate depot injectable does not increase prostate volume: study during up to 7 years on hypogonadic patients

Pisoschi Matei , Carsote Mara , Poiana Catalina , Staicu Dana Cristina , Peretianu Dan

Aim: Re-analysing the effect of injectable testosterone undecanoate depot (TUD) in hypogonadic patients.Materials and method: (A) Patients: at onset 210 men with hypogonadism (median age: 61.5 years). (B) Distribution: by decade; n=4, 12, 21, 54, 59, 43, 16, and 1. (C) TUD (NebidoR-Bayer-Schering) 1000 mg was injected one per 3 months i.m. (D) Prostate volume (PV) appreciated by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm...

ea0037ep146 | Reproduction, endocrine disruptors and signalling | ECE2015

Testosterone undecanoate 1000 mg at 3 months did not increased prostatic specific antigen level: January 2015

Pisoschi Matei , Carsote Mara , Poiana Catalina , Staicu Dana Cristina , Peretianu Dan

Aim: To find if testosterone undecanoate (TUD) 1000 mg injection (NebidoR; Bayer-Schering) at 3 months has a negative effect on prostate.Materials and method: i) PSA (ng/ml) registred before (T0) and after TUD at T1 (2 weeks) to T10 (7 years) (see Pisoschi, this Congress); ii) statistical analysis: t-test, simple correlation, and multiple regression.Results: (A) Patients at onset: 143 men, 18–96 years, average: 60.38;...

ea0035p689 | Male reproduction | ECE2014

Analysing by decade, testosterone undecanoat depot injectable does not increases prostate volume: study during up to 6 years on hypogonadic patients

Pisoschi Matei , Carsote Mara , Poiana Catalina , Staicu Cristina Daniela , Peretianu Dan

Aim: Re-analyzing the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.Materials & methods: (A) Patients: at onset 191 men with hypogonadism (median age: 64 years). (B) Distribution: by decade. (C) TUD (NebidoR-Bayer-Schering) 1000 mg was injected one per 3 months i.m. (D) Prostate volume (PV) by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm3), Aloka 550. (E). Time of analysis: be...

ea0070aep202 | Bone and Calcium | ECE2020

Body composition and adipokines influence upon bone mineral density and bone metabolism in renal transplant receivers

Matei Anca , Bilha Stefana , Constantinescu Daniela , Cianga Petru , Covic Adrian , Branisteanu Dumitru

Introduction: Renal transplant receivers (RTR) have a higher risk for osteoporosis, obesity and sarcopenia, which all seem to be interrelated. FGF23 and adipokine disorders, often recognized in RTR, might be involved in the fat-muscle-bone crosstalk. The current study aims to evaluate the influence of body compartiments and adipokines on bone mass in RTR.Methods: Thiscross-sectional study investigates the predictive role of body composition, adipokines (...

ea0032p663 | Male reproduction | ECE2013

Analysing by decade, testosterone undecanoat depot injectable does not increases prostate volume. Study during up to 6 years on hypogonadic patients

Peretianu Dan , Carsote Mara , Poiana Catalina , Cristina Staicu Daniela , Pisoschi Matei

Aim: Re-analyzing the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.Material-method: i) Patients: at onset 175 men with hypogonadism (median age: 64 years). ii) Distribution: by decade. iii) TUD (Nebido-Bayer-Schering) 1000 mg was injected one per 3 months i.m. iv) Prostate volume (PV) appreciated by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm3), Aloka 550. v) Time of analysis: before start...

ea0029p468 | Clinical case reports - Thyroid/Others | ICEECE2012

Exogenous thyrotoxicosis by consumption of pork sausage

Cano Megias M. , Diez J. , Perez Lopez G. , Garcia Villanueva M. , Iglesias P. , Matei A.

Background: Exogenous hyperthyroidism is a rare cause of thyrotoxicosis. It is caused by ingestion of excessive amounts of thyroid hormone, which could be intentional or surreptitious (known as factitious thyrotoxicosis). One of the most exceptional cause is the intake of meat or sausage containing thyroid tissue, inadvertently mixed with traces of muscles and other tissues of the animal’s neck (hamburger thyrotoxicosis). The clinical symptoms are indistinguishable from o...

ea0056p173 | Bone ' Osteoporosis | ECE2018

Is FGF23 a key factor in primary hyperparathyroidism?

Gatu Alina-Andreea , Velicescu Cristian , Repede Dan Ionut , Bilha Stefana , Florescu Alexandru , Matei Anca , Branisteanu Dumitru

Published data regarding the role of FGF23 in primary hyperparathyroidism and its prognostic applicability are scarce and discordant.Aims: To assess FGF23 profile in patients with primary hyperparathyroidism undergoing surgery.Matherials and methods: Longitudinal study involving 48 patients aged 30–80 years with primary hyperparathyroidism caused by solitary parathyroid adenoma, submitted to parathyroidectomy. We evaluated FGF...

ea0099p440 | Adrenal and Cardiovascular Endocrinology | ECE2024

The challenges of adrenal incidentaloma evaluation in dialysis patients

Florea Mihaela , Bilha Stefana , Popa Viviana , Puscasu Irina , Florescu Alexandru , Matei Anca , Leustean Letitia , Preda Cristina

Introduction: Chronic kidney disease (CKD) is associated with alterations in endogenous glucocorticoid regulation through various mechanisms: longer plasma cortisol half-life, reduced renal cortisol clearance, loss of 11b-HSD type 2 activity in the kidney contributing to an elevated cortisol/cortisone ratio, less effective hepatic metabolism of cortisol and, finally, hyperactivation of the hypothalamus-pituitary-adrenal axis due to acidosis, chronic stress, and inflammation.</...

ea0099ep930 | Adrenal and Cardiovascular Endocrinology | ECE2024

Silent yet aggressive: a case of large adrenocortical carcinoma with asymptomatic hypercortisolism

Larisa Robu , Beatrice Blesneac Ilona , Tarcau Otilia , Matei Anca , Teodoriu Laura , Florescu Alexandru , Preda Cristina

Introduction: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy arising from the adrenal cortex often with unexpected biological behavior. It can occur at any age, with two peaks of incidence: in the first and between fifth and seventh decades of life. Although ACC are mostly hormonally active, precursors and metabolites may be also produced by dedifferentiated and immature malignant cells.Case report: We report a rare and challenging case of...